Literature DB >> 28538744

Comorbidities of hidradenitis suppurativa.

Martina L Porter1, Alexa B Kimball2.   

Abstract

Hidradenitis suppurativa (HS) is an inflammatory skin disorder with many associated comorbidities, including obesity, metabolic syndrome, smoking, depression, arthritis, autoinflammatory syndromes, inflammatory bowel disease, and genetic syndromes. In addition, HS patients can suffer from a variety of diseases related to the chronic inflammatory nature of their HS such as cardiovascular disease and anemia. An understanding of these comorbidities and associations is essential for the management of HS, and routine screening for these entities should be considered in all HS patients. ©2017 Frontline Medical Communications.

Entities:  

Keywords:  arthritis; comorbidities; hidradenitis suppurativa; inflammatory bowel disease; obesity; smoking; squamous cell carcinoma

Mesh:

Year:  2017        PMID: 28538744     DOI: 10.12788/j.sder.2017.018

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  4 in total

1.  Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis.

Authors:  Partik Singh; Jonathan I Silverberg
Journal:  Arch Dermatol Res       Date:  2020-05-11       Impact factor: 3.017

2.  Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections.

Authors:  Erika L Crowley; Ashley O'Toole; Melinda J Gooderham
Journal:  SAGE Open Med Case Rep       Date:  2018-06-01

Review 3.  TNF-α inhibitors in the treatment of hidradenitis suppurativa.

Authors:  Kevin T Savage; Kelsey S Flood; Martina L Porter; Alexa B Kimball
Journal:  Ther Adv Chronic Dis       Date:  2019-05-27       Impact factor: 5.091

4.  Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.

Authors:  Øystein Grimstad; Bjørn Øivind Kvammen; Carl Swartling
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.